Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18

Thrombosis and Haemostasis

Volumn 114, Issue 6, 2015, Pages 1207-1217

  Hamad, Osama A ^a   Mitroulis, Ioannis ^b   Fromell, Karin ^a   Kozarcanin, Huda ^a   Chavakis, Triantafyllos ^b   Ricklin, Daniel ^c   Lambris, John D ^c   Ekdahl, Kristina N ^a,d   Nilsson, Bo ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Complement C3; Microparticles; Platelet leukocyte Complex; Platelets; PMN

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT RECEPTOR; FIBRINOGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; THROMBOPLASTIN; C5AR1 PROTEIN, HUMAN; COMPLEMENT COMPONENT C5A RECEPTOR; COMPSTATIN; CYCLOPEPTIDE; ITGAM PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN BINDING; RECOMBINANT PROTEIN; THROMBIN RECEPTOR PEPTIDE (42-47);

ANIMAL CELL; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; QUARTZ CRYSTAL MICROBALANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE RICH PLASMA; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHO CELL LINE; CRICETULUS; GENETIC TRANSFECTION; HAMSTER; IMMUNOLOGY; MEMBRANE MICROPARTICLE; METABOLISM; PROTEIN ANALYSIS; THROMBOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ANTIGENS, CD18; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CHO CELLS; COMPLEMENT ACTIVATION; COMPLEMENT C3; CRICETINAE; CRICETULUS; HUMANS; NEUTROPHILS; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTOR, PAR-1; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84983108465     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0162     Document Type: Article

References (45)

1. Cerletti C, Tamburrelli C, Izzi B, et al. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012; 129: 263-266.
2. Lappegard KT, Garred P, Jonasson L, et al. A vital role for complement in heart disease. Mol Immunol 2014; 61: 126-134.
3. Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum 2012; 42: 66-69.
4. Engstrom G, Hedblad B, Janzon L, et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Preven Rehab 2007; 14: 392-397.
5. Palikhe A, Sinisalo J, Seppanen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007; 99: 890-895.
6. Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147: 1713-1726.
7. Del Conde I, Cruz MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879.
8. Hamad OA, Nilsson PH, Wouters D, et al. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 2010; 184: 2686-2692.
9. Peerschke EI, Yin W, Grigg SE, et al. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006; 4: 2035-2042.
10. Saggu G, Cortes C, Emch HN, et al. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 2013; 190: 6457-6467.
11. Bauer EM, Zheng H, Comhair S, et al. Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PloS one 2011; 6: e28578.
12. Gushiken FC, Han H, Li J, et al. Abnormal platelet function in C3-deficient mice. J Thromb Haemost 2009; 7: 865-870.
13. Darbousset R, Delierneux C, Mezouar S, et al. P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice. Blood 2014; 124: 2575-2585.
14. Darbousset R, Thomas GM, Mezouar S, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012; 120: 2133-2143.
15. Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med 2008; 18: 103-107.
16. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010; 16: 887-896.
17. Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13: 1211-1220.
18. Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J 2012; 76: 1811-1818.
19. von Hundelshausen P, Koenen RR, Weber C. Platelet-mediated enhancement of leukocyte adhesion. Microcir 2009; 16: 84-96.
20. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
21. Siddiqui FA, Desai H, Amirkhosravi A, et al. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 247-253.
22. Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19: 225-233.
23. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-5281.
24. Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res 2013; 131: 191-197.
25. Ehlers R, Ustinov V, Chen Z, et al. Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha. J Exp Med 2003; 198: 1077-1088.
26. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). The J Exp Med 2000; 192: 193-204.
27. Chavakis T, Santoso S, Clemetson KJ, et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem 2003; 278: 45375-45381.
28. Santoso S, Sachs UJ, Kroll H, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-691.
29. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-2093.
30. Patko Z, Csaszar A, Acsady G, et al. Roles of Mac-1 and glycoprotein IIb/IIIa integrins in leukocyte-platelet aggregate formation: stabilization by Mac-1 and inhibition by GpIIb/IIIa blockers. Platelets 2012; 23: 368-375.
31. Hamad OA, Ekdahl KN, Nilsson PH, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6: 1413-14121.
32. Lood C, Eriksson S, Gullstrand B, et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis? Lupus 2012; 21: 1423-1432.
33. Pekna M, Nilsson L, Nilsson-Ekdahl K, et al. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 1993; 91: 404-409.
34. Schwendinger MG, Spruth M, Schoch J, et al. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol 1997; 158: 5455-5463.
35. Alaei S, Larcher C, Ebenbichler C, et al. Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun 1993; 61: 1395-1399.
36. Ross GD, Newman SL, Lambris JD, et al. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med 1983; 334-352.
37. Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007; 26: 1129-1139.
38. Andersson J, Ekdahl KN, Larsson R, et al. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol 2002; 168: 5786-5791.
39. Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005; 437: 505-511.
40. de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 1999; 29: 41-49.
41. Shimaoka M, Shifman JM, Jing H, et al. Computational design of an integrin I domain stabilized in the open high affinity conformation. Nature Strucr Biol 2000; 7: 674-678.
42. Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiol 2012; 217: 1106-1110.
43. Klapper Y, Hamad OA, Teramura Y, et al. Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials 2014; 35: 3688-3696.
44. Nilsson B, Nilsson UR. SDS denaturation of complement factor C3 as a model for allosteric modifications occurring during C3b binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation. Immunol Lett 1986; 13: 11-14.
45. Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci 2012; 4: 289-299.